Alembic Pharmaceuticals Limited has received final approval from the US Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for Fingolimod Capsules, 0.5 mg. This approval enables the company to market the product in the United States, further strengthening its presence in the regulated generics market.
Therapeutic Equivalence to Reference Drug
The approved formulation is therapeutically equivalent to the reference listed drug (RLD), Gilenya Capsules, 0.5 mg, developed by Novartis Pharmaceuticals Corporation. As a result, Alembic can offer a cost-effective alternative while maintaining the same safety and efficacy standards.
Indication: Treatment for Multiple Sclerosis
Fingolimod is a sphingosine 1-phosphate receptor modulator indicated for treating relapsing forms of Multiple Sclerosis. This includes clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive disease in patients aged 10 years and older. Patients and healthcare providers are advised to refer to the product label for detailed usage guidelines.
Market Opportunity and Growth Potential
According to IQVIA data, Fingolimod Capsules, 0.5 mg, recorded an estimated market size of approximately US$145 million for the 12 months ending December 2025. Therefore, this approval presents a meaningful commercial opportunity for Alembic in the US generics segment.
Strong ANDA Portfolio Expansion
With the latest approval, Alembic continues to expand its regulatory portfolio. The company now holds a cumulative total of 237 ANDA approvals from the USFDA, including 219 final approvals and 18 tentative approvals. As per the press release, the milestone reinforces Alembic’s strategy to strengthen its footprint in high-value therapeutic segments while delivering affordable medicines to global markets.
